All In Biotech

Drug Trial Radar · NCT06136507

Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A

An Open, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of Recombinant Human Coagulation Factor Ⅷ-Fc Fusion Protein (FRSW107) for Injection in Pediatric Patients With Severe Hemophilia A

Last checked: Nov 19, 2026Latest source record: Jun 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

76

Planned (sponsor's estimate)

Start

Dec 25, 2026

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
First posted
Nov 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 1 year, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was divided into four stages: screening period, main trial period, extension period and follow-up period. In the main trial, both groups received FRSW107 prophylactic therapy. The recommended initial dose of prophylactic administration was 50 IU/kg, the dose range was 25 to 50 IU/kg, and the recommended frequency of administration was once every three days (Q3D). The dose range could be adjusted according to the patient's response. The main trial period was prophylaxis up to ≥50 exposure days (EDs) and ≥6 months. The investigator may adjust the dose according to the clinical efficacy of the subjects (the occurrence of bleeding and its clinical manifestations) and the concentration of FⅧ valley according to the following principles. If necessary, the investigator may adjust the dosing interval according to the clinical efficacy of the subject (the occurrence of bleeding and its clinical manifestations) and the concentration of FⅧ. Investigators are advised to inform sponsors or their research partners when adjusting doses and dosing intervals during prophylaxis. After participants completed prophylaxis until ≥50EDs and ≥6 months, participants' willingness and investigator evaluation were used to decide whether to enter the extended trial. All subjects entering the extended phase continued with the original prophylactic regimen until 100EDs was dosed. During the main trial period and the extended preventive treatment period, if the subjects have breakthrough bleeding events requiring treatment, hemostatic treatment of breakthrough bleeding with investigational drugs can be performed. The researchers can refer to the treatment guidance for different degrees of bleeding in Table 6-1. Taking into account the subject's prophylactic dose, severity of bleeding, site and extent of bleeding, clinical status, and previous PK results (if any), the investigator determines the appropriate dose to administer (recommended dose range: 25 to 50 IU/kg) and dosing times until the investigator assessed significant control of bleeding episodes (e.g. reduction of pain and swelling) or return to pre-bleeding activity. If the bleeding episode stops, the subject will continue with the same dose and frequency of prophylactic medication as before the bleeding episode.

Conditions

  • Severe Hemophilia A

Interventions

  • FRSW107Drug

    experimental:Q3D.≥50EDs, Expansion phase:Q3D.100EDs

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ABRTime frame: 1year

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital Affiliated to Chongqing Medical University

    Chongqing, China

  • Guangzhou Women and Children Medical Center

    Guangzhou, China

  • Nanfang Hospital, Southern Medical University

    Guangzhou, China

  • Affiliated Hospital of Guizhou Medical University

    Guizhou, China

  • Children's Hospital, Zhejiang University School of Medicine

    Hangzhou, China

  • Anhui Children's Hospital

    Hefei, China

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, China

  • Nanjing Children's Hospital

    Nanjing, China

  • Affiliated Hospital of Qingdao University

    Qingdao, China

  • Shenzhen Children's Hospital

    Shenzhen, China

  • Shanxi Children's Hospital

    Taiyuan, China

  • Beijing Children's Hospital Affiliated to Capital Medical University

    Tianjing, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.